These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 14562807)

  • 21. Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.
    Barry MJ; Kaufman DS; Wu CL
    N Engl J Med; 2008 May; 358(20):2161-8. PubMed ID: 18480209
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention of prostate cancer.
    Stephenson AJ; Abouassaly R; Klein EA
    Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
    Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
    Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
    Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
    Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL
    Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A big study yields big questions.
    Zuger A
    N Engl J Med; 2003 Jul; 349(3):213-4. PubMed ID: 12867605
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevention of prostate cancer--the dilemma continues.
    Scardino PT
    N Engl J Med; 2003 Jul; 349(3):297-9. PubMed ID: 12824458
    [No Abstract]   [Full Text] [Related]  

  • 32. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea.
    Beer TM
    Health News; 2003 Aug; 9(8):1-2. PubMed ID: 12971313
    [No Abstract]   [Full Text] [Related]  

  • 33. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolution of the PCPT from clinical to molecular analyses.
    Hoque A
    Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
    [No Abstract]   [Full Text] [Related]  

  • 35. Finasteride to prevent prostate cancer: a new chapter.
    Harv Mens Health Watch; 2009 Jun; 13(11):1-4. PubMed ID: 19579321
    [No Abstract]   [Full Text] [Related]  

  • 36. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
    Serfling R; Shulman M; Thompson GL; Xiao Z; Benaim E; Roehrborn CG; Rittmaster R
    J Urol; 2007 Jun; 177(6):2352-6. PubMed ID: 17509357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of prostate cancer with finasteride.
    Roehrborn CG
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562804
    [No Abstract]   [Full Text] [Related]  

  • 38. New finasteride trial results aim to curb controversy.
    Bankhead C
    J Natl Cancer Inst; 2006 Aug; 98(16):1104-5. PubMed ID: 16912260
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Adolfsson J
    Eur Urol; 2009 May; 55(5):1074. PubMed ID: 19200637
    [No Abstract]   [Full Text] [Related]  

  • 40. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
    Villers A
    Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.